Electrical Storm: Mechanistic and Therapeutic Considerations to Avoid Death in the Survivors

Overview

Journal J Thorac Dis

Publisher AME Publishing Company

Specialty Pulmonary Medicine

Date 2019 Jan 12

PMID 30631553

Citations 1

Authors

Yukiomi Tsuji

Dobromir Dobrev

Affiliations

Soon will be listed here.

Citing Articles

Implantable cardioverter-defibrillator therapy in primary versus secondary prevention: Reliable prediction of appropriate therapies and mortality is still an unmet need.

Tsuji Y, Dobrev D Int J Cardiol Heart Vasc. 2021; 32:100740.

PMID: 33681454 PMC: 7910703. DOI: 10.1016/j.ijcha.2021.100740.

References

Bode F, Wiegand U, Raasch W, Richardt G, Potratz J . Differential effects of defibrillation on systemic and cardiac sympathetic activity. Heart. 1999; 79(6):560-7. PMC: 1728717. DOI: 10.1136/hrt.79.6.560. View

Anderson M . Calcium and stunning: when, from where, and what next?. J Cardiovasc Electrophysiol. 2002; 13(10):1025-6. DOI: 10.1046/j.1540-8167.2002.01025.x. View

Nikolski V, Efimov I . Electroporation of the heart. Europace. 2005; 7 Suppl 2:146-54. DOI: 10.1016/j.eupc.2005.04.011. View

Cevik C, Perez-Verdia A, Nugent K . Implantable cardioverter defibrillators and their role in heart failure progression. Europace. 2009; 11(6):710-5. DOI: 10.1093/europace/eup091. View

Tsuji Y, Hojo M, Voigt N, El-Armouche A, Inden Y, Murohara T . Ca(2+)-related signaling and protein phosphorylation abnormalities play central roles in a new experimental model of electrical storm. Circulation. 2011; 123(20):2192-203. DOI: 10.1161/CIRCULATIONAHA.110.016683. View

Tsai M, Huang C, Tsai S, Tsai C, Chen H, Cheng H . The difference in myocardial injuries and mitochondrial damages between asphyxial and ventricular fibrillation cardiac arrests. Am J Emerg Med. 2012; 30(8):1540-8. DOI: 10.1016/j.ajem.2012.01.001. View

Wang Y, Efimov I, Cheng Y . Electroporation induced by internal defibrillation shock with and without recovery in intact rabbit hearts. Am J Physiol Heart Circ Physiol. 2012; 303(4):H439-49. PMC: 3423145. DOI: 10.1152/ajpheart.01121.2011. View

Wagner S, Rokita A, Anderson M, Maier L . Redox regulation of sodium and calcium handling. Antioxid Redox Signal. 2012; 18(9):1063-77. PMC: 3567778. DOI: 10.1089/ars.2012.4818. View

Gasparini M, Proclemer A, Klersy C, Kloppe A, Lunati M, Martinez Ferrer J . Effect of long-detection interval vs standard-detection interval for implantable cardioverter-defibrillators on antitachycardia pacing and shock delivery: the ADVANCE III randomized clinical trial. JAMA. 2013; 309(18):1903-11. DOI: 10.1001/jama.2013.4598. View

10.

Tan V, Wilton S, Kuriachan V, Sumner G, Exner D . Impact of programming strategies aimed at reducing nonessential implantable cardioverter defibrillator therapies on mortality: a systematic review and meta-analysis. Circ Arrhythm Electrophysiol. 2014; 7(1):164-70. DOI: 10.1161/CIRCEP.113.001217. View

11.

Guerra F, Flori M, Bonelli P, Patani F, Capucci A . Electrical storm and heart failure worsening in implantable cardiac defibrillator patients. Europace. 2014; 17(2):247-54. DOI: 10.1093/europace/euu298. View

12.

Santangeli P, Muser D, Maeda S, Filtz A, Zado E, Frankel D . Comparative effectiveness of antiarrhythmic drugs and catheter ablation for the prevention of recurrent ventricular tachycardia in patients with implantable cardioverter-defibrillators: A systematic review and meta-analysis of randomized controlled.... Heart Rhythm. 2016; 13(7):1552-9. DOI: 10.1016/j.hrthm.2016.03.004. View

13.

Sterns L, Meine M, Kurita T, Meijer A, Auricchio A, Ando K . Extended detection time to reduce shocks is safe in secondary prevention patients: The secondary prevention substudy of PainFree SST. Heart Rhythm. 2016; 13(7):1489-96. DOI: 10.1016/j.hrthm.2016.03.022. View

14.

Sapp J, Wells G, Parkash R, Stevenson W, Blier L, Sarrazin J . Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs. N Engl J Med. 2016; 375(2):111-21. DOI: 10.1056/NEJMoa1513614. View

15.

Brewster J, Sexton T, Dhaliwal G, Charnigo R, Morales G, Parrott K . Acute Effects of Implantable Cardioverter-Defibrillator Shocks on Biomarkers of Myocardial Injury, Apoptosis, Heart Failure, and Systemic Inflammation. Pacing Clin Electrophysiol. 2017; 40(4):344-352. PMC: 5395321. DOI: 10.1111/pace.13037. View

16.

Dietl A, Maack C . Targeting Mitochondrial Calcium Handling and Reactive Oxygen Species in Heart Failure. Curr Heart Fail Rep. 2017; 14(4):338-349. DOI: 10.1007/s11897-017-0347-7. View

17.

Grandi E, Dobrev D . Non-ion channel therapeutics for heart failure and atrial fibrillation: Are CaMKII inhibitors ready for clinical use?. J Mol Cell Cardiol. 2017; 121:300-303. PMC: 6358017. DOI: 10.1016/j.yjmcc.2017.10.010. View

18.

Neef S, Steffens A, Pellicena P, Mustroph J, Lebek S, Ort K . Improvement of cardiomyocyte function by a novel pyrimidine-based CaMKII-inhibitor. J Mol Cell Cardiol. 2018; 115:73-81. PMC: 5820112. DOI: 10.1016/j.yjmcc.2017.12.015. View

19.

Lebek S, Plossl A, Baier M, Mustroph J, Tarnowski D, Lucht C . The novel CaMKII inhibitor GS-680 reduces diastolic SR Ca leak and prevents CaMKII-dependent pro-arrhythmic activity. J Mol Cell Cardiol. 2018; 118:159-168. DOI: 10.1016/j.yjmcc.2018.03.020. View

20.

Chatzidou S, Kontogiannis C, Tsilimigras D, Georgiopoulos G, Kosmopoulos M, Papadopoulou E . Propranolol Versus Metoprolol for Treatment of Electrical Storm in Patients With Implantable Cardioverter-Defibrillator. J Am Coll Cardiol. 2018; 71(17):1897-1906. DOI: 10.1016/j.jacc.2018.02.056. View